Regenxbio和日本神职人员基因疗法合作伙伴,由日本神职人员负责销售。 Regenxbio and Nippon Shinyaku partner on gene therapies, with Nippon Shinyaku to handle sales.

Regenxbio和日本新作合作,开发了MPS I和II的基因疗法,由日本新作处理商业化。 Regenxbio and Nippon Shinyaku have partnered to develop gene therapies for MPS I and II, with Nippon Shinyaku handling commercialization. Regenxbio将提前收到1.1亿美元,根据里程碑和销售额可能额外支付高达7亿美元。 Regenxbio will receive $110 million upfront, with potential additional payments of up to $700 million based on milestones and sales. 合作的目的是将RGX-121和RGX-111的疗法带给病人,利用Regenxbio的基因疗法专门知识和日本新政的商业能力。 The collaboration aims to bring therapies RGX-121 and RGX-111 to patients, leveraging Regenxbio's gene therapy expertise and Nippon Shinyaku's commercial capabilities.